Literature DB >> 12021083

Oral tolerance, systemic immunoregulation, and autoimmunity.

Stephan Strobel1.   

Abstract

Convincing clinical and experimental evidence suggests that the disturbance of important immunoregulatory and suppressive immunological events induced after oral (mucosal) antigen exposure (oral tolerance) may lead to allergic and autoimmune diseases. Within a variety of factors, age of the host and timing of antigen (food) administration are important characteristics in the development of food allergic disease. Induction of tolerance is seen as a Th2 skewed response, which on one side may prevent harmful mucosal immune reactions but on the other side may contribute to adverse responses in the susceptible individual. The primary mechanisms by which tolerance may be mediated include deletion, anergy, suppression, "ignorance," and apoptosis. Cell-mediated delayed hypersensitivity reactions (Th1), which are implicated in the development of autoimmune and gastrointestinal diseases, are particularly well suppressed. Regulatory events after mucosal exposure of antigen are not well characterized and remain controversial. The balance between tolerance (suppression) and sensitization (priming) is dependent on several factors, such as: (a) genetic background, (b) nature and dose of antigen, (c) frequency of administration, (d) age at first antigen exposure, (e) immunological status of the host, (f) antigen transmission via breast milk, and others. Overall there is evidence in rodents that multiple low-dose feeds are more likely to induce regulatory cytokines (e.g., TGF-beta, IL-10, IL-4) in part secreted by CD4+CD25+ T regulatory cells. Despite the powerful suppressive effects of oral autoantigen exposure observed in experimental models of autoimmune diseases (including bystander suppression), their translation into clinical trials of autoimmune diseases has not yet yielded the expected beneficial results.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021083     DOI: 10.1111/j.1749-6632.2002.tb02946.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

1.  TGF-beta signaling is required for the function of insulin-reactive T regulatory cells.

Authors:  Wei Du; F Susan Wong; Ming O Li; Jian Peng; Hao Qi; Richard A Flavell; Robert Sherwin; Li Wen
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

2.  Maternal country of origin, breast milk characteristics and potential influences on immunity in offspring.

Authors:  U Holmlund; P Amoudruz; M A Johansson; Y Haileselassie; A Ongoiba; K Kayentao; B Traoré; S Doumbo; J Schollin; O Doumbo; S M Montgomery; E Sverremark-Ekström
Journal:  Clin Exp Immunol       Date:  2010-10-05       Impact factor: 4.330

3.  Oral administration of type II collagen suppresses pro-inflammatory mediator production by synoviocytes in rats with adjuvant arthritis.

Authors:  C H Ding; Q Li; Z Y Xiong; A W Zhou; G Jones; S Y Xu
Journal:  Clin Exp Immunol       Date:  2003-06       Impact factor: 4.330

4.  World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines.

Authors:  Alessandro Fiocchi; Jan Brozek; Holger Schünemann; Sami L Bahna; Andrea von Berg; Kirsten Beyer; Martin Bozzola; Julia Bradsher; Enrico Compalati; Motohiro Ebisawa; Maria Antonieta Guzman; Haiqi Li; Ralf G Heine; Paul Keith; Gideon Lack; Massimo Landi; Alberto Martelli; Fabienne Rancé; Hugh Sampson; Airton Stein; Luigi Terracciano; Stefan Vieths
Journal:  World Allergy Organ J       Date:  2010-04-23       Impact factor: 4.084

5.  Anti-Interleukin-9 Antibody Increases the Effect of Allergen-Specific Immunotherapy in Murine Allergic Rhinitis.

Authors:  Ji Hyeon Shin; Do Hyun Kim; Boo Young Kim; Sung Won Kim; Se Hwan Hwang; Joohyung Lee; Soo Whan Kim
Journal:  Allergy Asthma Immunol Res       Date:  2017-05       Impact factor: 5.764

Review 6.  Nonmurine animal models of food allergy.

Authors:  Ricki M Helm; Richard W Ermel; Oscar L Frick
Journal:  Environ Health Perspect       Date:  2003-02       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.